Wink

Wink Therapeutics is a biotechnology company focused on developing next-generation CAR-T cell therapies specifically designed to treat solid tumors. Founded by pioneers in the field of cellular immunotherapy from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, the company aims to overcome the historical limitations of CAR-T therapies in non-liquid cancers. Their approach involves engineering T cells with enhanced persistence, potency, and the ability to navigate the immunosuppressive tumor microenvironment. By leveraging advanced genetic engineering, Wink Therapeutics seeks to provide curative options for patients with difficult-to-treat solid malignancies.